Valuation: Beta Bionics, Inc.

Market Cap 86Cr 77Cr 71Cr 65Cr 121.75Cr 8.17TCr 123.7Cr 852.38Cr 334.2Cr 4.26TCr 323.02Cr 316.14Cr 14TCr P/E 2026 *
-8.1x
P/E 2027 * -7.84x
Enterprise Value 71Cr 63Cr 59Cr 54Cr 100.99Cr 6.78TCr 102.61Cr 707.05Cr 277.22Cr 3.54TCr 267.95Cr 262.24Cr 11TCr EV / Sales 2026 *
5.74x
EV / Sales 2027 * 4.46x
Free-Float
99.18%
Yield 2026 *
-
Yield 2027 * -
1 day-5.55%
1 week-7.26%
Current month-13.86%
1 month-23.71%
3 months-5.44%
6 months+25.96%
Current year-46.34%
1 week 16.32
Extreme 16.32
18.56
1 month 16.32
Extreme 16.32
23.56
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Sell

Executive/Senior Manager

-370 0.0007%
22/09/26 Sell

Director

-6,430 0.0143%
16/09/26 Sell

Executive/Senior Manager

-30,779 0.0684%
Change 5-day change 1-year change 3-year change Capi.($)
-5.55%-7.26%-18.33% - 86Cr
-0.93%+4.86%+28.03%+42.34% 26TCr
-1.06%+4.20%+9.56%+8.07% 16TCr
-0.27%+0.65%-4.36%+54.96% 15TCr
+0.57%+3.88%-55.27%-12.03% 6.43TCr
+1.47%+5.90%-13.25%-13.43% 5.19TCr
-0.85%+4.81%+9.39%+49.25% 5.03TCr
-1.70%+1.63%+16.02%+23.13% 4.99TCr
-1.47%+1.42%+21.88%+53.89% 4.88TCr
-1.62%+0.73%+30.59%+70.27% 4.29TCr
Average -1.14%+2.56%+2.43%+30.72% 8.76TCr
Weighted average by Cap. -0.70%+4.12%+8.48%+32.22%

Financials

2026 *2027 *
Net sales 12Cr 11Cr 10Cr 9.32Cr 18Cr 1.18TCr 18Cr 123.16Cr 48Cr 615.92Cr 47Cr 46Cr 1.96TCr 18Cr 16Cr 15Cr 14Cr 26Cr 1.73TCr 26Cr 180.88Cr 71Cr 904.57Cr 69Cr 67Cr 2.88TCr
Net income -9.37Cr -8.33Cr -7.72Cr -7.02Cr -13Cr -889.23Cr -13Cr -93Cr -36Cr -464.04Cr -35Cr -34Cr -1.48TCr -10Cr -9.19Cr -8.52Cr -7.75Cr -15Cr -981.2Cr -15Cr -102.39Cr -40Cr -512.03Cr -39Cr -38Cr -1.63TCr
Net Debt -15Cr -13Cr -12Cr -11Cr -21Cr -1.39TCr -21Cr -145.33Cr -57Cr -726.77Cr -55Cr -54Cr -2.32TCr -4.63Cr -4.11Cr -3.81Cr -3.47Cr -6.54Cr -438.98Cr -6.65Cr -46Cr -18Cr -229.08Cr -17Cr -17Cr -730.27Cr
Projected Income Statement - Annual - Beta Bionics, Inc.
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
16/26/16 $16.35 -5.55% 6,60,849
15/26/15 $17.31 +2.61% 13,31,132
14/26/14 $16.87 -4.64% 8,92,915
13/26/13 $17.69 -0.95% 5,91,352
12/26/12 $17.86 +1.30% 8,20,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Beta Bionics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
16.35USD
Average target price
24.24USD
Spread / Average Target
+48.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Beta Bionics, Inc.
  1. Stock Market
  2. Stocks
  3. BBNX Stock